Needham Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $29

Benzinga · 05/07 18:51
Needham analyst Joseph Stringer maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and lowers the price target from $40 to $29.